Articles tagged with Cancer Medication
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at the University of Houston have developed a novel technology to monitor membrane protein trafficking in real-time using bioluminescence. This allows for the study of cellular processes and drug development for heart disease, metabolic disorders, cancer, infectious diseases, COVID-19, and others.
The American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, recognizing distinguished scientists who have propelled innovation and progress against cancer. The 2022 class consists of 33 luminaries from various scientific disciplines.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Researchers found that genetic ancestry is associated with differences in biology of acute lymphoblastic leukemia (ALL) and is an independent factor contributing to treatment outcomes. Children from East Asian and South Asian backgrounds had better survival rates than Caucasian children, with Indian children having the best outcomes.
A Phase 3 clinical study of selinexor as maintenance therapy for advanced or recurrent endometrial cancer showed a 30% decrease in hazard for progression or death compared to the placebo-controlled group. Patients with functional p53 genes saw the most pronounced effect, with median progression-free survival at 10 months longer.
Researchers Miao-Ping Chien and Daan Brinks have developed a method to detect aggressive cancer cells, which can help identify the genetic profile of individual cells and develop targeted medicines. This breakthrough has the potential to improve treatment outcomes for patients with cancer.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
Researchers at NTU Singapore have developed a novel drug delivery system using protein-based microdroplets that can bypass the cell membrane and deliver biomacromolecules effectively. This breakthrough enables faster, safer, and more effective treatments for diseases such as cancer and metabolic disorders.
Researchers at Weill Cornell Medicine have found that an enzyme called ART1 can modify a receptor on tumor-fighting immune cells, triggering their death. Blocking ART1 increased the presence of these immune cells within tumors and slowed or stopped tumor growth in animal models.
Researchers found that sequencing drug combinations can enhance the anti-tumor immune response in liver cancer, potentially reducing toxic drug exposure. The new strategy primes the tumor with an immune checkpoint inhibitor before using a multikinase inhibitor, enhancing its effectiveness.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers at the University of Bologna have developed a new targeted cancer therapy based on a genetically modified phage that selectively eliminates tumour cells. The virus is engineered to transport a drug activated by light to target tumour cells, reducing side effects.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
A collaborative study from Monash University has identified a new immune checkpoint, PTP1B, that can be exploited for cancer therapy. Inhibiting this protein in T cells enhances the body's immune response to cancer, helping to repress tumour growth.
A research team has devised a novel strategy to overcome chemotherapy resistance in cancer by boosting the pro-apoptotic BAX protein and targeting its inhibitor, BCL-XL. The two-drug combination achieved significant success against apoptosis-resistant human tumor cell lines and xenograft models, with minimal side effects.
A study published in Nature Communications reveals the precise molecular structure of siponimod, a multiple sclerosis drug, and its interactions with S1P receptors. This knowledge may lead to the development of more targeted therapies that reduce side effects.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
Researchers developed a novel scaffold to grow breast tumors with reduced immune variability, enabling more accurate immunotherapy drug testing. The new model replicates treatment-resistant breast cancer microenvironments and predicts patient responses to therapy.
Researchers found that some painkillers and fever medications may help fight infection, while others can weaken the immune system. The review highlights the need for more studies on the impact of these medicines on infectious diseases.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Researchers developed a new imaging approach called VascuViz to visualize blood vessels at different spatial scales. The method enables detailed mathematical models and complementary images to clarify the role of blood flow in health and disease, advancing our understanding of tissues throughout the body.
A modeling study suggests that breast cancer overdiagnosis may occur in about 15% of screen-detected cases, rather than the estimated 30%. This could spare around 25,000 women unnecessary treatment. Researchers used data from the Breast Cancer Surveillance Consortium to estimate the rate of overdiagnosis.
Computer simulations reveal metformin's effectiveness in targeting diabetes and some cancers, but also its negative consequences for others. Researchers emphasize the need for precision medicine to individualize treatment based on patient profiles.
A new study suggests that microorganisms hindering treatment have a greater influence than those enhancing it, with around 1 year after treatment begins the gut microbiota becomes a dominant factor. The research sheds light on the interaction between the gut microbiome and cancer immunotherapy response.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
Scientists at the Princess Máxima Center for Pediatric Oncology discovered a new combination treatment strategy for childhood T-cell acute lymphoblastic leukemia (T-ALL) by analyzing protein activity. The study found that blocking specific proteins, such as LCK and SRC, in combination with an overactive chain reaction of INSR/IGF-1R, k...
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at University of Cincinnati develop a new probe and imaging technique to study lysosomes, aiding in cancer and neurodegenerative disease research. The probe, known as EC Green, enables multidimensional analysis of lysosome dynamics and provides stable tracking capabilities.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
Scientists have developed a new computational tool that mimics the processes of natural selection, producing proteins for medicinal and household uses. This innovation reduces the time required for laboratory evolution from months or years to just days.
A new synthetic substance, PECS-101, has been shown to prevent neuropathic pain caused by chemotherapy while improving cancer treatment outcomes. The study, conducted in mice, found that PECS-101 had no adverse effects and did not cause dependence.
Scientists at Japan Advanced Institute of Science and Technology have created nanoengineered bacteria for photothermal cancer immunotheranostics. The synthesized nanoparticles showed powerful photothermal conversion, high biocompatibility, and excellent tumor selectivity, facilitating clear fluorescent tumor visualization.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
A phase 3 trial demonstrates that adding darolutamide to standard therapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer. The treatment also delays disease progression and reduces need for additional therapies.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
A recent study found that women have a 34% higher risk of severe toxicity than men in cancer treatment, with higher risks for immunotherapy and targeted therapies. The analysis of over 20,000 patients from more than 200 clinical trials supports the idea that sex may independently modulate drug toxicity.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
Researchers discover that chemotherapy triggers the secretion of mucins in colorectal cancer cells, forming a physical barrier that prevents drugs from reaching their intended target. The study found potential new biomarkers for disease prognosis and a promising treatment strategy using NCX blockers like SN-6.
A new study by Virginia Commonwealth University researchers finds that triplatin is effective against triple negative breast cancer with high sulfated glycosaminoglycans (sGAG) levels. The drug accumulates inside cancer cells, causing damage and slowing tumor growth.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
The opioid crisis in the US has reached epidemic levels, with over 100,000 drug overdose deaths reported for the first time. The US Centers for Disease Control and Prevention attributes the rise to abuse of synthetic opioid fentanyl and the COVID-19 pandemic.
A genome study found significant variation in human ribosomal RNA (rRNA) genes based on geographic ancestry, particularly in the 28S rRNA segment. This discovery suggests that these variants may be important for understanding cancer development and functionally assessing their impact on ribosome functions.
A clinical trial has found selinexor to be effective in shrinking tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer. The treatment induced responses in certain patients and allowed some to stay on the medication for over 12 months.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A recent study led by University at Buffalo researchers found that photobiomodulation reduces inflammation, improves blood flow and heals wounds up to 19 days faster. Light therapy accelerated skin healing from cancer radiation therapy by an average of 49-42 days.
A new analysis links genetic variants associated with high blood levels of lipoprotein A to a higher risk of prostate cancer, including advanced or early-age-onset cases. The study found no significant associations for other blood lipids.
USC researchers will use $18.5 million funding to study colorectal cancer in Hispanic patients, aiming to close the gap in understanding the disease and developing effective treatments. The project aims to improve patient engagement in genomic research and develop culturally relevant educational materials.
A research team has developed a new cancer treatment that targets lymph nodes using a prodrug that selectively reacts with glutathione to release nitric oxide. In a metastasis mouse model, the mice treated with the drug showed significantly reduced weight of metastatic cancer cells and improved survival rates.
Researchers have developed a novel combination of two drugs delivered in nanoparticles that extend the survival of mice with medulloblastoma. The treatment targets the mTOR pathway and reduces off-target toxicity, making it a potential less toxic alternative to current treatments.